CHICAGO, JUNE 23, 2022 - Xentria Inc., a biotech company focused on developing novel biologics to address unmet clinical needs, presented its first set of data showing its novel biologic, XTMAB-16, has the potential to reduce the formation of sarcoidosis granulomas.
Sarcoidosis is a chronic, inflammatory disorder that can affect multiple organs and bodily systems including the skin, eyes, heart, and central nervous system. More than 90% of cases involve the lungs. Symptoms range from asymptomatic to severe — including respiratory problems, blindness, neurological disease, and cardiac death. There is no tumor necrosis factor (TNF)-inhibitor currently FDA approved for the treatment of sarcoidosis.
Key findings from the data include:
“These new data are a promising first step in the continued evaluation of XTMAB-16 as a potential therapy for patients with sarcoidosis,” said Thomas Shea, President of Xentria. “The release of this new data reinforces our commitment to the sarcoidosis rare disease community and our mission to develop new breakthrough treatment.”
XTMAB-16 works to limit tissue injury and fibrosis caused by the disease by targeting the cellular signals regulating inflammation, called cytokines. The study evaluated the effect of treatment with XTMAB-16 in an in vitro model using cells taken from patients with lungs and/or lymph nodes affected by active sarcoidosis.
“While there are currently medications available to try to manage the symptoms of this rare disease, the available treatments have serious limitations, including limited efficacy and unacceptable side-effects, and there is a pressing need for better treatments,” said investigator Elliott D. Crouser, M.D., Professor of Internal Medicine, Wexner Medical Center, The Ohio State University. “I look forward to working with Xentria to further evaluate XTMAB-16’s potential to reduce disease manifestations and improve the quality of life and care of patients with sarcoidosis.”
Data were presented at the American Thoracic Society 2022 International Conference in San Francisco, CA, on May 17, 2022.
XTMAB-16 Attenuates Granuloma Formation in a Human In Vitro Sarcoidosis Model
About Sarcoidosis Granuloma
Sarcoidosis is a chronic, multisystem inflammatory disorder of unknown etiology that is characterized by the presence of non-caseating and non-necrotizing epithelioid granulomas (as opposed to granulomas caused by infections, such as tuberculosis), accompanied by infiltration of mononuclear cells and destruction of microarchitecture.
XTMAB-16 is a chimeric human-murine IgG1 anti-TNF monoclonal antibody being developed as a novel biologic product for the treatment of sarcoidosis.
Xentria, whose name stems from the word “centrality”, was founded in 2020 and is an innovative biopharmaceutics company whose primary focus is to build an expansive product pipeline of cost-effective and efficacious biologics to address critical unmet need for patients suffering from rare diseases, immunologic disorders and oncological conditions. Headquartered in Chicago, with partners in Israel and China, the company is dedicated to research and development, clinical science, manufacturing, and commercialization, driven to treat the clinical and social burdens of diseases while fostering sustainable growth.
To learn more about Xentria visit www.xentria.com.
Jacqui Wilmot, Senior Director
Erin Williams, Director
Noopur Singh, Senior Manager, Site Engagement and Patient Recruitment
 Crouser ED, White P, Caceres EG, et al. A novel in vitro human granuloma model of sarcoidosis and latent tuberculosis infection. Am J Respir Cell Mol Bio. 2017; 57:487-498.